Ikena Oncology, Inc.

As of November 7, 2024, Ikena Oncology, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics, including a -32.50% ROE and poor performance compared to peers and the S&P 500, with a current stock price of 1.34.

As of June 11, 2025, Ikena Oncology, Inc. is in a mildly bearish trend, indicated by daily moving averages and overall monthly indicators, despite some mildly bullish signals from weekly MACD and KST.

Ikena Oncology, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $9 million and a market cap of $65.63 million. Key metrics include a negative P/E ratio, no dividend yield, and a return on equity of -32.50%.

As of Jun 18, Ikena Oncology, Inc. has a market capitalization of 65.63 million, with net sales of 0.00 million and a net profit of -41.70 million over the last four quarters. The company reported shareholder's funds of 125.93 million and total assets of 141.51 million as of Dec 24.